Moving the Needle on Alzheimer’s Disease with an Anti-Oligomer Antibody
Moving the Needle on Alzheimer’s Disease with an Anti-Oligomer Antibody
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In the current issue of the
Journal
, van Dyck and colleagues
1
report the encouraging results of an 18-month, phase 3 trial of lecanemab that involved participants with early Alzheimer’s disease. The primary end point was the change from baseline in the score on the Clinical Dementia Rating–Sum of Boxes. Key secondary end points were t...
Alternative Titles
Full title
Moving the Needle on Alzheimer’s Disease with an Anti-Oligomer Antibody
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2761182852
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2761182852
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMe2214981
